KYORIN Pharmaceutical Co., Ltd.
4569・Prime Market・Pharmaceuticals
Governance
As a company with a Board of Corporate Auditors, the Board of Directors consists of 6 directors (including 3 independent outside directors, an outside ratio of 50%). The company has established a voluntary "Committee on Compensation and Nomination," in which independent outside directors hold a majority, ensuring a highly transparent nomination and compensation process.
Risk Management
The company has established a Risk Management Committee chaired by the executive officer in charge, which promotes risk mitigation and prevention based on the Risk Management Regulations and other rules. A system is in place to establish an Emergency Response Headquarters headed by the President in the event of an emergency, and similar committees have also been established at group companies to oversee risk management across the group as a whole.
Shareholder Returns
Annual dividend for FY2026 (ending March 2026) was maintained at ¥57 per share (interim ¥20 + year-end ¥37), but the dividend payout ratio rose to 96.1% due to a significant decline in net income. For FY2027 (ending March 2027), the annual dividend is planned to be reduced to ¥25 (interim ¥10 + year-end ¥15). During the fiscal year, the company retired treasury shares (equivalent to ¥11,421 million).
Dividend Policy
The basic policy is to maintain stable dividends with consideration of DOE (dividend on equity ratio). The annual dividend for FY2026 (ending March 2026) is ¥57 per share (interim ¥20 + year-end ¥37, of which the year-end dividend consists of an ordinary dividend of ¥32 plus a special dividend of ¥5), with total dividends of ¥3,314 million, a dividend payout ratio of 96.1%, and a dividend-on-net-assets ratio of 2.3%. For FY2027 (ending March 2027), due to deteriorating business performance, the annual dividend is planned to be reduced to ¥25 (interim ¥10 + year-end ¥15), with the payout ratio expected to be 96.9%. Dividends are paid twice a year, interim and year-end.
ESG
The company endorses the TCFD recommendations, setting targets to reduce CO2 emissions by 46% in FY2030 (versus FY2015 levels) and to achieve carbon neutrality by 2050. In terms of human capital, it aims for a 15% ratio of female managers (FY2029 target) and a male childcare leave uptake rate of 90% or higher, and under its Health Management Declaration, it is promoting initiatives such as a 100% health checkup participation rate.
Last updated: June 18, 2026